Incyte Corporation
INCY Healthcare Biotechnology
Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.
Follow INCY
Incyte Corporation (INCY) Free cash flow
Incyte Corporation's free cash flow for fiscal 2025 was $1.3B, up 465.4% from $235.2M in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.9B. Over the past ten years it has ranged from −$312.0M (fiscal 2020) to $1.3B (fiscal 2025) — the current reading is the highest in ten years. Incyte Corporation ranks 3rd of 628 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $1.3B | 465.38% |
| FY2024 | $235.2M | (47.62%) |
| FY2023 | $449.0M | (49.67%) |
| FY2022 | $892.1M | 56.93% |
| FY2021 | $568.5M | — |
| FY2020 | −$312.0M | — |
| FY2019 | $632.6M | 140.76% |
| FY2018 | $262.7M | — |
| FY2017 | −$204.0M | — |
| FY2016 | $184.5M | 190.95% |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $495.2M | 39.84% |
| Mar 2026 | $354.2M | (32.08%) |
| Dec 2025 | $521.4M | 0.34% |
| Sep 2025 | $519.6M | 1,924.55% |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| INCY Incyte Corporation | $1.9B |
| RPRX Royalty Pharma PLC compare | $1.3B |
| EXEL Exelixis, Inc. compare | $1.2B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $819.9M |
| BNTX BioNTech SE Sponsored ADR compare | $500.7M |
| ASND Ascendis Pharma A/S compare | $387.5M |
| INSM Insmed, Inc. compare | −$807.7M |
| ROIV Roivant Sciences Ltd. compare | −$821.1M |
| GMAB Genmab A/S Sponsored ADR compare | −$6.3B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on INCY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement